Research programme: molecular glue degrader cancer therapeutics - Degron Therapeutics
Latest Information Update: 23 Jun 2022
At a glance
- Originator Degron Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action CRBN protein modulators; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 18 Jun 2022 Early research in Cancer in China (unspecified route) (Degron Therapeutics pipeline; June 2022)